Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen

Entrada Therapeutics (NASDAQ:TRDA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Oppenheimer assumed coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Entrada Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $18.50.

Entrada Therapeutics Price Performance

TRDA opened at $11.93 on Friday. The business has a fifty day moving average price of $11.64 and a 200 day moving average price of $9.39. Entrada Therapeutics has a 12 month low of $4.93 and a 12 month high of $13.65. The stock has a market capitalization of $456.68 million, a price-to-earnings ratio of -3.45 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. On average, research analysts anticipate that Entrada Therapeutics will post 1.12 earnings per share for the current year.

Insider Transactions at Entrada Therapeutics

In related news, CFO Kory James Wentworth sold 11,388 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $13.02, for a total value of $148,271.76. Following the completion of the transaction, the chief financial officer directly owned 121,510 shares of the company’s stock, valued at $1,582,060.20. This represents a 8.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Nathan J. Dowden sold 11,894 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $13.05, for a total value of $155,216.70. Following the completion of the transaction, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at $2,591,573.40. This trade represents a 5.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 39,475 shares of company stock worth $508,069. Company insiders own 8.11% of the company’s stock.

Institutional Trading of Entrada Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC lifted its position in shares of Entrada Therapeutics by 9.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock worth $176,000 after buying an additional 1,560 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Entrada Therapeutics by 7.1% in the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after buying an additional 1,620 shares during the last quarter. Great Lakes Advisors LLC grew its position in shares of Entrada Therapeutics by 5.5% in the 4th quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock valued at $445,000 after buying an additional 2,239 shares during the last quarter. Intech Investment Management LLC raised its stake in Entrada Therapeutics by 15.7% during the 2nd quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock worth $119,000 after acquiring an additional 2,397 shares in the last quarter. Finally, Quadrature Capital Ltd raised its stake in Entrada Therapeutics by 13.5% during the 4th quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after acquiring an additional 2,424 shares in the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.